Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models.

摘要: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19), a pandemic that has claimed over 700,000 human lives. The only SARS-CoV-2 antiviral, for emergency use, remdesivir, targeting viral polymerase complex. PF-00835231 pre-clinical lead compound with an alternate target, main protease 3CL pro (M ). Here, we perform comparative analysis and remdesivir in A549 +ACE2 cells, using isolates two major clades. antiviral both clades, and, this assay, statistically more potent than remdesivir. A time-of-drug-addition approach delineates timing early life cycle steps validates PF-00835231's time action. Both potently inhibit polarized airway epithelial cultures. Thus, our study provides vitro evidence potential as effective SARS-CoV-2, addresses concerns from non-human models, supports further studies compound.